Home » Formulations » Infrastructure

Infrastructure

MSN Labs
Formulating Health
  • APIs
  • Formulations
  • CRAMS

APIs

MSN has 8 API manufacturing units with all the major regulatory approvals. The facilities can manufacture products covering 35 therapies including Oncology & Prostaglandins.

Regulatory Approvals

  • PIC/S
  • USFDA
  • WHO:GMP
  • EUGMP
  • Hamburg, Germany
  • ISO 9001: 2008
  • DSIR Recognition
  • Korean FDA
  • Cofepris
  • Department of Science & Technology, Govt. of India
  • Department of Scientific and Industrial Research, Govt. of India
  • Solvenia

Features

  • Fully equipped manufacturing blocks with attached clean air systems
  • More than 400 SS/GL/HP reactors ranging from 50-4000 ltr
  • Dedicated pilot plants (with clean air systems) for scale-up studies
  • Process R&D team at each plant
  • Cryogenic facilities (-80 to 250 degree C)
  • Purified water distribution loop confirming to USP
  • In house Micronization capabilities
  • Clean rooms at every block
  • Dedicated Microbiology Labs
  • Wide range of analytical euipment including GCs, HPLCs with PDA, UV spectrometers, IR, PSD, DSC & XRD
  • Abosulte compliance with Safety, Health & Environment

Formulations

MSN has 3 formulation facility one for Oncology.The facilities can manufacture products covering 35 therapies including Oncology & Prostaglandins.

Regulatory Approvals

  • USFDA
  • PIC/S
  • WHO:GMP
  • EU:GMP
  • INVIMA
  • NAFDAC-Nigeria
  • PPB-Kenya
  • TFDA-Tanzania
  • NDA-Uganda
  • MOH-Namibia
  • MOH-Yemen
  • ISO 9001:2008
  • FMHACA-Ethiopia
  • PMPB-Malawi
  • SAUMP-Ukraine
  • ANVISA-Brazil

Features

  • Fully equipped Formulation & Analytical method development labs
  • Dedicated facilities for R&D, pilot & commercial operations
  • Capable of manufacturing Tablets, Capsules, Ampoules, Vials & Lyophilised Vials
  • Capable of wet/dry granulation, direct compression, film coating and blister/strip/alu-alu packing.
  • Manufacturing sites of class 10,000 & class 1000 controlled conditions. Dedicated AHUs to control individual areas. Terminal Hepa filters in core processing area

CRAMS

Facilities

  • 42 Labs
  • Pilot labs
  • World-class dedicated Analytical R&D in TDC for CRAMSN

Features

API
  • Reactions - Pressure, Cryogenic, Metal hydride,Catalytic, Aliphatic-Aromatic-Heterocyclic, & Multi-step synthesis.
  • Polymorphism
  • Particle Size
  • Bulk density
  • Impurities synthesis
Formulations
  • Tablets - IR, SR/ER, Bi-Layered, Chewable, Dispersible and Sublingual.
  • Capsules- IR and DR.
  • Injectables- Vials and Ampoules.